Cargando…

Immune Checkpoint Blockade for the Treatment of Hodgkin Lymphoma

Classical Hodgkin lymphoma is biologically different than other lymphomas. The cancer cells only occupy a small amount of the lymph node and evade the immune system by amplification of PD-L1 and PD-L2. Therefore, checkpoint inhibitors are a logical treatment option for Hodgkin lymphoma patients to u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Adam Yuh, Schnitter, Joseph Michael, Gordon, Leo I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8882667/ https://www.ncbi.nlm.nih.gov/pubmed/35237537 http://dx.doi.org/10.2147/ITT.S284988

Ejemplares similares

Immune Checkpoint Inhibition in Hodgkin Lymphoma
por: Moy, Ryan H., et al.
Publicado: (2018)

Immune-Checkpoint Blockade Therapy in Lymphoma
por: Kuzume, Ayumi, et al.
Publicado: (2020)

The Role of Immune Checkpoint Inhibitors in Classical Hodgkin Lymphoma
por: Meti, Nicholas, et al.
Publicado: (2018)

Classical Hodgkin’s Lymphoma in the Era of Immune Checkpoint Inhibition
por: De Re, Valli, et al.
Publicado: (2019)

Tumor microenvironment contribution to checkpoint blockade therapy: lessons learned from Hodgkin lymphoma
por: Carbone, Antonino, et al.
Publicado: (2023)

Expression of the immune checkpoint receptor TIGIT in Hodgkin’s lymphoma
por: Li, Wenchao, et al.
Publicado: (2018)

Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma
por: Oncale, Melody B, et al.
Publicado: (2017)

Activating the Antitumor Immune Response in Non-Hodgkin Lymphoma Using Immune Checkpoint Inhibitors
por: Joshi, Maansi, et al.
Publicado: (2020)

Discovering the fibroblastic reticular cell in the immune tumor microenvironment in lymphoma
por: Lin, Adam Yuh, et al.
Publicado: (2023)

Immune checkpoint blockade in HIV
por: Gubser, Celine, et al.
Publicado: (2022)

Immune-related adverse events in the treatment of non-Hodgkin lymphoma with immune checkpoint inhibitors
por: Argnani, Lisa, et al.
Publicado: (2022)

Efficacy of Immune Checkpoint Blockade and Biomarkers of Response in Lymphoma: A Narrative Review
por: Perdikis-Prati, Sarah, et al.
Publicado: (2023)

Checkpoint Inhibitors in Relapsed/Refractory Classical Hodgkin Lymphoma
por: Tarekegn, Kidist, et al.
Publicado: (2021)

Update on checkpoint blockade therapy for lymphoma
por: Kline, Justin, et al.
Publicado: (2015)

Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors
por: Allen, Pamela B, et al.
Publicado: (2017)

Current Clinical Applications and Future Perspectives of Immune Checkpoint Inhibitors in Non-Hodgkin Lymphoma
por: Apostolidis, John, et al.
Publicado: (2020)

Neutrophils in the era of immune checkpoint blockade
por: Faget, Julien, et al.
Publicado: (2021)

Updates in the Role of Checkpoint Inhibitor Immunotherapy in Classical Hodgkin’s Lymphoma
por: Nakhoda, Shazia, et al.
Publicado: (2022)

Immune checkpoint blockade therapy for bladder cancer treatment
por: Kim, Jayoung
Publicado: (2016)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
por: Wessely, Anja, et al.
Publicado: (2020)

Immune checkpoint blockade in glioblastoma: from tumor heterogeneity to personalized treatment
por: Arrieta, Víctor A., et al.
Publicado: (2023)

Immune checkpoint blockade in ovarian cancer
por: Weiss, Lukas, et al.
Publicado: (2016)

Immune Checkpoint Inhibition in Classical Hodgkin Lymphoma: From Early Achievements towards New Perspectives
por: De Goycoechea, Diego, et al.
Publicado: (2019)

Immune phenotypes and checkpoint molecule expression of clonally expanded lymph node-infiltrating T cells in classical Hodgkin lymphoma
por: Ballhausen, Alexej, et al.
Publicado: (2022)

Immune-Checkpoint Blockade and Active Immunotherapy for Glioma
por: Ahn, Brian J., et al.
Publicado: (2013)

The role of neoantigen in immune checkpoint blockade therapy
por: Yi, Ming, et al.
Publicado: (2018)

Predictive biomarkers for tumor immune checkpoint blockade
por: Tong, Mengting, et al.
Publicado: (2018)

Acquired Resistance to Immune Checkpoint Blockade Therapies
por: Zhao, Xianda, et al.
Publicado: (2020)

Rethinking immune checkpoint blockade: ‘Beyond the T cell’
por: Liu, Xiuting, et al.
Publicado: (2021)

Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
por: Yi, Ming, et al.
Publicado: (2019)

Role of tumor gene mutations in treatment response to immune checkpoint blockades
por: Wang, Manni, et al.
Publicado: (2019)

Gastric Cancer in the Era of Immune Checkpoint Blockade
por: Figueroa-Protti, Lucía, et al.
Publicado: (2019)

Immune checkpoint blockade and CAR-T cell therapy in hematologic malignancies
por: Wang, Hao, et al.
Publicado: (2019)

Corticosteroids and immune checkpoint blockade
por: Min, Le, et al.
Publicado: (2015)

Checkpoint CD47 expression in classical Hodgkin lymphoma
por: Gholiha, Alex Reza, et al.
Publicado: (2022)

A Review of Hodgkin Lymphoma in the Era of Checkpoint Inhibitors
por: Schimmoeller, Christopher J, et al.
Publicado: (2023)

Emerging Role of Immune Checkpoint Blockade in Pancreatic Cancer
por: Macherla, Shravanti, et al.
Publicado: (2018)

Optimizing radiotherapy with immune checkpoint blockade in hepatocellular carcinoma
por: Choi, Changhoon, et al.
Publicado: (2019)

Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs
por: Drakes, Maureen L., et al.
Publicado: (2020)

Prospects for combining immune checkpoint blockade with PARP inhibition
por: Li, Anping, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_9bkm6mlmt4uvht6khdokjvrbt9